Dashboard
Monday, November 2, 2026
Key numbers
Model status
Not released
Best candidate fda_iq@0.5.0: 3 of 9 release checks passed
Drugs tracked
711
In the drug database, listings not yet reviewed included
Upcoming PDUFAs
4
Next 30 days
FDA decisions
2
Novel first-cycle decisions, last 30 days
Upcoming PDUFA dates
| Drug / ticker | CT-VCA | P(Approve) | PDUFA | Days to go | Watchlist |
|---|---|---|---|---|---|
| Cemdisiran | 28 days left in the periodDate not exact | ||||
| BXCL501 | 12 days to go | ||||
| Ivonescimab | 12 days to go | ||||
| Povetacicept | 28 days to go |
Dates come from company and FDA disclosures and can change. P(Approve) stays “Not released” until a model passes its release checks. How estimates work
Model release checks
- FDA approval model (FDA IQ)
- Not released
- Best candidate
- fda_iq@0.5.0 sha256:0b83ea99…f233c
- Release checks passed
- 3 of 9 release checks passed
- Status
- Serving blocked: no model has passed the release gates; the best candidate passes 3 of 9.
Estimates appear only after a model passes all nine release checks on past FDA decisions and a second admin approves it. Until then no drug shows a probability, a range or a confidence level.
Recent FDA decisions
All decisionsApproved on first review
HIBSAGO
Bepirovirsen · GLAXOSMITHKLINE LLC
Approved on first review
HOVILPR
Pritelivir · AICURIS ANTI-INFECTIVE CURES AG
Data provided by the U.S. Food and Drug Administration. Facts only: no estimate is shown for past decisions.
Health News Breaking and top news, sector and specialty news, Health Market, experts and opinions, Health Investor, the FDA calendar and AlphaDoc.
Breaking news
View all Breaking news- Xinhua Silk Road: 2026 International Exchange on Women and Children's Health held in Boao, Hainan (opens in a new tab)
- LUNGevity Foundation Unites Communities to Advance Progress During 2026 Lung Cancer Awareness Month (opens in a new tab)
- Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding Product Commercialization Footprint (opens in a new tab)
- Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026 (opens in a new tab)
- EASE Secures US$9.5 Million to Expand AI-Enabled Medical Imaging and Surgical Robotics in South Africa and Ghana (opens in a new tab)
FDA safety alerts
View all FDA safety alerts- Vitality Works Inc. Recalls 365 Whole Foods Market Ashwagandha Capsules Sold Nationwide Due to Potential Salmonella Contamination (opens in a new tab)
- Platelet Factor 4 (PF4) Radioimmunoassay Recall: Instrumentation Laboratories Removes HemosIL AcuStar HIT-IgG(PF4-H) (opens in a new tab)
- Hospital Glucose Meter Correction: Nova Biomedical Updates Use Instructions for StatStrip Glucose Hospital Meter Systems (opens in a new tab)
- SLR Food Distribution Inc. Recalls Wise Wife Brand Ground Cinnamon Due to Elevated Lead Levels (opens in a new tab)
- Early Alert: Medline Removes or Corrects All Medline Brand Beds and Accessories (opens in a new tab)
Daily Pulse
Free morning email
Upcoming FDA dates and the latest health headlines each morning, each item linked to its source.
Create a free account to choose your feeds and send time.
Recent insider trades
All insider trades- OtherBrennan Daniel J.
$400.3K795 shares
- SellMalik Fady Ibraham
$224K3,500 shares
- OtherMalik Fady Ibraham
$27.3K3,500 shares
- OtherSulzberger Gabrielle
$5K3.9976 shares
- OtherLUCIANO JUAN R
$15.9K12.8325 shares
Form 4 filings from SEC EDGAR. Insider filings are public records and are not a recommendation.
Health Deals
All dealsNo deals are published yet. Latest deal news:
- Acquisition expands Principle's bedside imaging services for long-term care providers in Missouri and Illinois (opens in a new tab)
- Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. (opens in a new tab)
- PeierTech Announces Completion of Majority Investment by HSG (opens in a new tab)